Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Severe hypoglycaemia ups ACS risk in diabetics

17 Oct 2019

The risk of acute coronary syndrome (ACS) appears to be elevated following episodes of severe hypoglycaemia, a recent study has found.

Researchers performed a retrospective, population-based analysis on the data of 7,909,626 diabetes patients (aged 35 years; 41 percent male). The absolute risk of ACS was defined as the need for emergency percutaneous coronary intervention following severe hypoglycaemia.

Over 5,087,611,521 person-days of follow-up, 37,486 cases of ACS were reported. The resulting absolute risk was 2.9 per 1,000 person-years. In those with vs without type 1 diabetes, the corresponding rates were 2.1 and 3.0 per 1,000 person-years, respectively.

Within 2 years, 48,118 at-risk patients experienced a severe hypoglycaemic episode. These patients were more likely than their no-episode counterparts to develop ACS (3.0 vs 2.7 per 1,000 person-years). They also tended to be older and more likely to receive insulin therapy, antiplatelet drugs and anticoagulants.

Adjusted regression analysis confirmed that severe hypoglycaemia was a significant risk factor for ACS (hazard ratio, 1.016, 95 percent CI, 1.012–1.021).

This ACS risk changed over time, varying according to the time elapsed after the severe hypoglycaemia episode. At 10 days after such an episode, for instance, the absolute risk of ACS was 10.6 per 1,000 person-years. This dropped to 2.2 and 2.5 per 1,000 person-years after 11–90 and 91–365 days had elapsed, respectively.

The present findings indicate that severe hypoglycaemia needs to be monitored and treated well in patients with diabetes, said researchers. Future studies are needed to better characterize the time interval after hypoglycaemia during which ACS risk should be tightly managed.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.